UroVysion for diagnosis, monitoring and prediction.
UroVysion provides additional clinical value for bladder cancer diagnosis in conjunction with cytology and cystoscopy
UroVysion is a urine-based molecular test which can help guide physicians in making clinical decisions regarding patient care. UroVysion is intended to be used in combination with cytology and cystoscopy and may provide the most diagnostic benefit when standard of care is negative or unclear.
UroVysion provides greater insights during monitoring of bladder cancer, especially in patients where cytology and cystoscopy are negative, equivocal or suspicious. UroVysion has a high negative predictive value providing confidence in the effectiveness of treatment plans and when used in patients undergoing Bacillus Calmette-Guerin (BCG) therapy, a UroVysion positive result indicates patients are 3-5 times more likely to have tumor recurrence.